SFA — Sopharma AD Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedMid CapNeutral

Annual income statement for Sopharma AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,293	1,450	1,616	1,675	1,894
Cost of Revenue
Gross Profit	270	270	311	324	337
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,253	1,412	1,564	1,609	1,800
Operating Profit	39.9	38.5	51.6	66.3	94.2
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	88.4	31.4	97.6	85.1	111
Provision for Income Taxes
Net Income After Taxes	84.4	25.3	91.7	76.3	99.1
Minority Interest
Net Income Before Extraordinary Items
Net Income	87	29.8	89.5	71.1	95.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	87	29.8	89.5	71.1	95.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.837	0.3	0.553	0.76	0.742
Dividends per Share